The biopharmaceutical industry continues to develop, and the pharmaceutical machine industry will meet more opportunities and challenges

【Chemical Machinery Equipment Network Market Analysis ] Recently, Tofflon released the 2021 semi-annual performance forecast
.
According to the announcement, in the first half of 2021, the company is expected to achieve a net profit of 309-344 million yuan attributable to the parent, a year-on-year increase of 80-100%; deducting the non-attributable net profit to the parent of 275-310 million yuan, a year-on-year increase of 102.
67-128.
10%
.
Regarding the expected performance of Tofflon's 2021 semi-annual report exceeding expectations, industry analysts believe that this is mainly due to the increase in business brought about by the epidemic
.
In the future, under the background of the accelerated commercialization of vaccines, Tofflon may be expected to usher in more opportunities
.

It is worth mentioning that, in addition to being optimistic that vaccine equipment will bring considerable performance gains to it and further open up domestic alternative space, the industry also predicts that its biopharmaceutical sector has great business potential and will continue for business growth in the future
.
It is understood that Tofflon started product research and development in 2015.
At present, its research and development progress and product richness are very eye-catching in China.
It already has a freezing system, a shaking table, a wave typeReactors , stainless steel reactors, separation and purification systems and other products
.
Based on the current development status, in the long run, Tofflon will be expected to occupy a higher market share in the domestic replacement of biopharmaceutical equipment, enter a new life cycle, and open up a new round of room for growth
.

 

　　In fact, under the background of the rapid rise of Biotech companies and the expansion of CDMO industry in recent years, biopharmaceutical equipment has obviously ushered in new opportunities for development, and the space for national replacement is also constantly opening
.
In addition to Tofflon, the industry believes that domestic pharmaceutical machine companies that have laid out earlier in this field and have certain R&D strength and rich products are expected to demonstrate competitive advantages and gain new growth space
.

 

　　The reason for this conclusion is that the biopharmaceutical process involves many links such as separation, liquid preparation, inactivation, and liquid storage, and the types of biopharmaceutical equipment products applied are also very rich, including bioreactors,Freezers , sterilizers,
etc.
With the continuous development of the biopharmaceutical industry, these biopharmaceutical equipment has actually become a common demand of biopharmaceutical enterprises
.
Therefore, under the continuous expansion of the biopharmaceutical market in the future, these devices are expected to have a more considerable market
.

 

　　However, while seeing the opportunity, the industry also proposed that the biopharmaceutical equipment industry will face huge challenges
.
It is reported that for a long time, the localization rate of biopharmaceutical equipment in China has been low, and the overall innovation capability of the industry is not high, so that most of the equipment purchased by domestic biopharmaceutical enterprises is mostly imported equipment
.
Therefore, in the context of the continuous development of the biopharmaceutical industry, the industry believes that domestic biopharmaceutical equipment companies need to increase their research and development efforts, break the bottleneck of "stuck neck", and create biopharmaceutical equipment with higher value for users to meet the high demand of pharmaceutical companies.
The need for quality production
.

 

　　As far as the author understands, a large number of domestic biopharmaceutical equipment companies have been making efforts to the high-end biopharmaceutical equipment market through innovation
.
Take the bioreactor as an example, which is a very core and critical equipment for biopharmaceuticals
.
In view of the problems of low reliability and high energy consumption of domestic bioreactors, some companies have developed and produced reliable, energy-saving, practical and beautiful bioreactor equipment by integrating domestic and foreign product design and manufacturing processes.
Improve the production efficiency of pharmaceutical companies
.

 

　　In addition, there are also some domestic pharmaceutical equipment enterprises, which are promoting the rapid development of enterprises by absorbing various professional talents, developing and introducing new technologies in the fermentation industry
.
For example, a fermenter enterprise, in order to develop serialized and specialized biological fermentation equipment, has established a research center through cooperation with universities, and has carried out close cooperation with scientific research institutes and universities
.

 

　　Overall, the prospects for the biopharmaceutical industry are very promising
.
However, from the current domestic situation, the degree of automation, informatization and intelligence of domestic biopharmaceutical enterprises is not high enough, and there is a distance from "pharmaceutical industry 4.
0"
.
Therefore, while ushering in opportunities, related biopharmaceutical equipment also needs to seize opportunities with one hand and innovation with one hand, in order to continuously bring more practical value to users and help the better development of the biopharmaceutical industry
.

 

　　Original title: With the continuous development of the biopharmaceutical industry, the pharmaceutical machine industry will usher in more opportunities and challenges